SCHEMBL26951937

CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CSC[C@@H](C(=O)NCC(=O)N[C@@H](CCCCNC(=O)c2ccc(C=O)cc2)C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C1=O

nearest known ligand 0.47

Predicted protein targets (top 13)

	gene	UniProt	supporting neighbours	confidence
▸	KLKB1	P03952	7/20	0.47

▸	KEAP1	Q14145	1/20	0.45

▸	NFE2L2	Q16236	1/20	0.45

▸	KLK5	Q9Y337	2/20	0.44

▸	CD274	Q9NZQ7	2/20	0.44

▸	SLC6A3	Q01959	1/20	0.43

▸	ALB	P02768	1/20	0.43

▸	PDCD1	Q15116	1/20	0.43

▸	EPHA2	P29317	1/20	0.42

▸	PLAU	P00749	1/20	0.42

▸	PIN1	Q13526	3/20	0.42

▸	GRB2	P62993	1/20	0.41

▸	CIB1	Q99828	1/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL26951916	0.95	KEAP1 (0.48)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL23743537	0.93	KLKB1 (0.48)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL26951743	0.92	KLKB1 (0.49)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL23743610	0.92	KLK5 (0.49)	KLKB1KLK5ALBPLAUPIN1
SCHEMBL26951558	0.91	KLKB1 (0.47)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL26952055	0.91	KLKB1 (0.48)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL26952071	0.90	KEAP1 (0.51)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL23743518	0.88	KLKB1 (0.46)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL26951904	0.87	CTSG (0.48)	KLKB1KEAP1NFE2L2KLK5CD274
SCHEMBL26951915	0.86	KEAP1 (0.49)	KLKB1KEAP1NFE2L2KLK5CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230398224-A1	TARGETED PLASMA PROTEIN DEGRADATION	NOVARTIS AG (CH)	2023-12-14	—	—	US	disclosed
US-20230398224-A1	TARGETED PLASMA PROTEIN DEGRADATION	NOVARTIS AG (CH)	2023-12-14	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230398224-A1	TARGETED PLASMA PROTEIN DEGRADATION	M6PR, ASGR1, IGF2R	KLKB1 1521/4885KEAP1 4411/4885NFE2L2 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.